VRTX - Company ID 0000875320
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported revenue of $12.00B for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $12.00B | +8.9% |
| FY 2024 | $11.02B | +11.7% |
| FY 2023 | $9.87B | +10.5% |
| FY 2022 | $8.93B | +17.9% |
| FY 2021 | $7.57B | +22.1% |
| FY 2020 | $6.21B | +49.1% |
| FY 2019 | $4.16B | +36.6% |
| FY 2018 | $3.05B | +22.5% |
| FY 2017 |
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported revenue of $12.00B for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, VERTEX PHARMACEUTICALS INC / MA's revenue grew from $1.41B to $12.00B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.49B |
| +46.2% |
| FY 2016 | $1.70B | +64.9% |
| FY 2015 | $1.03B | +77.9% |
| FY 2014 | $580.41M | -52.1% |
| FY 2013 | $1.21B | -20.6% |
| FY 2012 | $1.53B | +8.3% |
| FY 2011 | $1.41B | - |